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Abstract
Background: Infertility is common and in vitro fertilization (IVF) is a widely used treatment. In IVF
the need increases and the effectiveness and appropriateness decrease by age. The purpose of this
study was to describe allocation of resources for IVF by women's age, socioeconomic position, area
of residence and treatment sector (public vs. private) and to discuss how fairly the IVF resources
are allocated in Finland.
Methods: Women who received IVF between 1996 and 1998 (N = 9175) were identified from the
reimbursement records of the Social Insurance Institution (SII). Information on IVF women's
background characteristics came from the Central Population Register and the SII, on treatment
costs from IVF clinics and the SII, and on births from the Medical Birth Register. The main outcome
measures were success of IVF by number of cycles and treated women, expenditures per IVF
cycles, per women, per live-birth, and per treatment sector, and private and public expenditures.
Expenditures were estimated from health care visits and costs.
Results: During a mean period of 1.5 years, older women (women aged 40 or older) received 1.4
times more IVF treatment cycles than younger women (women aged below 30). The success rate
decreased by age: from 22 live births per 100 cycles among younger women to 6 per 100 among
older women. The mean cost of a live birth increased by age: compared to younger women, costs
per born live birth of older women were 3-fold. Calculated by population, public expenditure was
allocated most to young women and women from the highest socioeconomic position. Regional
differences were not remarkable.
Conclusion: Children of older infertile women involve more expense due to the lower success
rates of IVF. Socioeconomic differences suggest unfair resource allocation in Finland.
Background
Equity in health care assumes equal access to care based
on need regardless of the patients' background character-
istics. In impaired fertility, a dilemma arises from the
increase with age of the need for health care, while its
health impact decreases. Women's ability to spontane-
ously become pregnant and have a live birth decreases
with age, leading to a greater need for infertility treatment
such as in vitro fertilization (IVF, including intracytoplas-
mic sperm injections (ICSI) and frozen embryo transfers),
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thermore, the health risks for the woman and baby
increase by age. Decreased fertility is common; about 10–
15% of couples are estimated to experience it at some
point in their lives [2]. In Finland, besides age, no other
significant socioeconomic or regional differences in infer-
tility rates have been found [3].
IVF is costly and in countries where IVF is offered only in
the private sector its availability depends on a couple's
ability to pay [4,5]. In France, where IVF costs are fully
covered by public resources, the use of IVF did not differ
according to women's socioeconomic position [6]. In
countries where IVF services are offered both in the public
and in the private sector, wealthy couples can shorten
their waiting times by using services in both sectors [7]. In
Finland, the private sector is an important provider of IVF:
over 60% of all IVF treatments are provided by private
clinics [8]. However, the use of private services is partly
covered by national health insurance: 60% of doctors' fees
and a part of the cost of the examinations are reimbursed
according to a fixed scale of charges. The part of the fee
that exceeds the fixed charge is not reimbursable. In the
public sector, patients pay a small user charge for their
clinic visits. In both sectors about 50% of the drug costs
are reimbursed by the Social Insurance Institution.
A key question in regard to fairness or equity in infertility
treatment is how scarce health care resources can be dis-
tributed equitably with the maximum benefit to public
health [9]. How can health care resources be allocated
fairly? Should women with "greater need" but less chance
of success be favoured or should women with "more ben-
efit" (younger and better chance of success) be favoured?
Health care costs for IVF treatment by women's age have
been described previously [10] but empirical data that
would quantify this question have not been given, nor has
the distribution of private and public expenditure been
estimated. The purpose of this study is to describe the allo-
cation of IVF resources by women's age, socioeconomic
position, area of residence, and treatment sector (public
vs. private), as well as to discuss whether the IVF resources
are allocated fairly in Finland.
Methods
The cohort of women having received IVF between 1996
and 1998 in Finland (N = 9175) has already been
described [11], as well as their background characteristics
[7]. In brief, using a pre-designed algorithm (presented in
detail earlier, [11]), women were identified from the reim-
bursement files of the Social Insurance Institution (SII),
which covers the whole Finnish population. According to
the algorithm all women born between 1940 and 1981
having received reimbursements for any of the drugs in
the following groups during the 1996–1998 period were
picked from the Drug Register: clomifen, gonadotrophin,
GnRH-agonist, and a progesterone drug Lugesteron. For
the women having bought drugs in the above-mentioned
groups, drugs from the following groups were addition-
ally included: human chorionic gonadotrophin, eastra-
diol and a progestin drug (dydrogesterone). For each
woman the treatment cycles were formed by using this
drug data. The cycles were linked to the Procedure Regis-
ter, with codes for ovum pick-up, cultivation of ovum,
intracytoplasmic sperm injection, and embryo transfer. By
using all the gathered information, the cycles were classi-
fied into other ART (assisted reproduction including ovu-
lation induction with or without insemination) and IVF
by using the specific inclusion criteria [11].
The socioeconomic position of the women was defined by
using their own occupation as detailed in the Central Pop-
ulation Registry, and classified automatically into five cat-
egories according to the national classification compiled
by Statistics Finland: upper white-collar workers, lower
white-collar workers, blue-collar workers, others (entre-
preneurs, students, pensioners, unemployed women and
women with an unclassified position) and unknown posi-
tion [12]. The sector (public vs. private) was defined by
using information on reimbursements and prescribing
physicians' codes. All treatment cycles that were started
after the beginning of January 1996 and before the end of
December 1998 were included. The mean follow-up time
was 1.5 years (range 0.5–3 years). Health of IVF women
were followed until the end of 2000 by using different
health care registers [13].
Direct costs of IVF treatments (see Additional file 1: Type
of IVF cycle, expenditures included in cost calculations in
each type of the cycle, as well as type and data source of
expenditures by the care sector) were obtained from the
SII, a private clinic (one of the largest private infertility
clinics, PRCL), the Helsinki University Central Hospital
(HUCH) and an earlier Finnish study by Koivurova 2005
(STUK) [14]. Direct costs included medications, visits,
routine examinations (radiological and laboratory tests),
interventions including ovum pick-up, ovum cultivation,
ICSI, and embryo transfers, as well as cost of equipment
and trained staff. Expenditures were partly based on aver-
age costs (AVER) in clinics, partly on estimations (EST)
and partly on exact paid and reimbursed costs (REAL, see
Additional file 1). About 30% of interrupted cycles in the
private sector included ovum pick-up, and this was extrap-
olated to the public sector, for which this data was not
available. ICSI was used in 21% of cycles in the private
sector and because 65% of ICSIs were made in the private
sector during the study period, we estimated that in the
public sector 19% of all cycles were ICSI. Indirect costs
such as costs for travel and sick leave were not included.Page 2 of 8
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(excluding reimbursements from the SII). Public expendi-
tures include costs paid by the health care system (exclud-
ing user charges). All costs and reimbursements have been
inflated to correspond to 2005 prices (in euros) using a
consumer price index compiled by Statistics Finland.
Data on women were linked to the Finnish Medical Birth
Register to identify live births resulting from IVF. Data on
identified children were linked to other health care regis-
ters until the end of 2004 to follow-up the health of IVF
children [15]. To measure treatment success, live births
per initiated cycle (all live births per all cycles) and per
treated woman (only one live birth per woman) were cal-
culated. Multiple pregnancies with two or more live
infants were calculated as one. The mean price of different
types of IVF cycles by care sector were calculated as well as
private, public, and total expenditures by women's back-
ground characteristics and by live births. To count
expenditure by population groups to show distribution of
IVF expenditures across all women in the total popula-
tion, we used the mean population of females aged 20–49
in Finland by socioeconomic position and area of resi-
dence according to census information for 1995 and 2000
available from Statistics Finland. Men were not included,
because regardless of male or female factor infertility, in
most cases the women are treated (drugs, ovum pick-ups,
and embryo transfers) and expenditures of treatments
(also ICSI) are billed from and reimbursed to the women.
The actual distribution of costs within the family was not
available.
The study plan was approved by the STAKES research eth-
ics committee (18th September 1998). For register link-
ages, the National Data Protection Authority was
consulted and permissions from the registry keepers
obtained.
Results
During the mean 1.5 year study period, IVF women
received on average 2.7 cycles (Table 1) resulting in at
least one live birth for 40% of women (Table 2). The suc-
cess rate per cycle was on average 15%.
The costs of different types of IVF cycles are given in Table
3. Of the total IVF costs, 36% came from drugs, 21% from
interventions, and 42% from other direct costs (data not
shown). During the mean 1.5 year follow-up, total costs
per treated woman were EUR 6500, of which 40% were
paid by women themselves (from private sources) and
60% from public sources (data not shown). In the private
sector, the out-of-pocket payment was 50% and in the
public sector 24% of total expenditures. The cost of a live
birth was on average EUR 16 000 (Table 4). In the popu-
lation-based calculation showing the distribution of IVF
expenditures across the whole population of fertile-age
women(aged 20–49), the expenditures during the study
period of 1996 to 1998 were EUR 60 per woman (Table
5), of which EUR 24 were paid by women themselves and
EUR 36 from public sources.
The use, success and expenditures of IVF were age-depend-
ant. Numbers and rates of women having received IVF
Table 1: Numbers and rates (per 1000 female population) of women having received IVF and number of treatment cycles per treated 
women by women's background characteristics and treatment sector in the study period (mean 1.5 years).
Number Population rate Number of cycles per treated women
Age 20–29 30–34 35–39 40+ Total 20–29 30–34 35–39 40+ Total 20–29 30–34 35–39 40+ Total
Socioeconomic position
Upper white-collar 367 856 727 368 2318 14 30 24 4 13 2.3 2.8 2.9 3.1 2.8
Lower white-collar 1072 1613 1256 510 4451 13 25 17 2 9 2.2 2.7 2.8 3.0 2.6
Blue-collar 460 479 372 173 1484 8 16 12 1 6 2.3 2.6 2.7 3.0 2.6
Others * 330 284 182 126 922 2 5 3 1 2 2.2 2.7 2.6 2.8 2.5
Area of residence †
Urban 1439 2185 1780 800 6204 6 18 15 2 7 2.2 2.7 2.8 3.1 2.7
Semi-Urban 331 476 337 154 1298 8 17 11 1 6 2.1 2.8 2.8 3.0 2.6
Rural 454 566 415 215 1650 10 18 11 1 6 2.3 2.7 2.8 2.7 2.6
Sector
Public 938 1242 873 175 3228 NA NA NA NA NA 1.9 2.2 2.4 2.2 2.2
Private 987 1585 1354 902 4828 NA NA NA NA NA 2.2 2.7 2.7 2.9 2.6
Both 304 405 310 100 1119 NA NA NA NA NA 3.1 4.4 4.6 5.3 4.2
Total 2229 3232 2537 1177 9175 7 18 14 2 7 2.2 2.7 2.8 3.0 2.7
* Entrepreneurs, students, pensioners, unemployed, and women with an unclassified or unknown position. † Excluding women with unknown area 
of residence (n = 23). NA = Not availablePage 3 of 8
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the treatment was more intense for older women (number
of cycles per woman) (Table 1). The success rate per cycle
and per woman decreased by age (Table 2); the number of
needed cycles for live birth increased by age (Table 4). The
higher treatment intensity among older women did not
compensate for the lowered success rate, and about 47%
of women aged under 30 and only 17% of women aged
40 or older succeeded in achieving a live birth after the
treatment period (mean 1.5 years) (Table 2).
The unit expenditure of IVF did not vary much between
age-groups, but older women were paid more of the total
expenditures from their own pockets; 37% among women
under 30 years, 38% among women aged 30–34 years,
40% among women aged 35–39 years, and 48% among
women aged 40–49 years. Total expenditures per live
birth increased by age, being 3.6 times higher among
older women compared to the younger women (Table 4).
Expenditures per population were highest among women
aged 30–34 and then decreased (Table 5), due to the lesser
use of IVF among older women (Table 1).
The use, success and expenditures of IVF also varied some-
what by socioeconomic position. Women from the high-
est socioeconomic position received more cycles and on a
population-based examination used IVF twice as much as
the blue-collar women in every age-group (Table 1) as
well as spent more of their own money for IVF treatment
compared to blue-collar women regardless the age of the
women (data not shown). About 25% of white-collar
women aged under 30 succeeded in achieving a live-birth,
Table 3: Women's own and society costs of one IVF cycle by the type of treatment and by the treatment sector (euros).
Public sector Private sector All cycles
IVF without embryo transfer Median Mean (Range) Median Mean (Range) Median Mean (Range)
Own 450 570 (130–5870) 1130 1350 (690–6170) 810 940 (130–6170)
Society 1290 1410 (980–6710) 920 1060 (380–5890) 1160 1250 (380–6710)
Total 1740 1980 (1110–12570) 2030 2410 (1070–11990) 1900 2180 (1070–12570)
IVF with embryo transfer
Own 850 940 (170–4240) 1620 1750 (540–8860) 1340 1490 (170–8860)
Society 2960 3050 (2300–6330) 1790 1880 (520–7840) 2160 2260 (520–7840)
Total 3800 3990 (2470–10570) 3450 3640 (1060–16700) 3640 3750 (1060–16700)
Frozen embryo transfer
Own 140 190 (110–2200) 380 540 (210–7060) 330 410 (110–7100)
Society 810 860 (800–2850) 450 580 (180–7310) 660 680 (180–7310)
Total 950 1050 (910–5040) 810 1130 (400–14370) 930 1100 (400–14370)
Table 2: Success of IVF treatment by women's background characteristics and treatment sector.
Live births/cycle * Live births/treated women †
Age 20–29 30–34 35–39 40+ Total 20–29 30–34 35–39 40+ Total
Socioeconomic position
Upper white-collar 0.25 0.18 0.13 0.06 0.15 0.55 0.49 0.38 0.20 0.42
Lower white-collar 0.23 0.17 0.14 0.05 0.16 0.49 0.46 0.37 0.15 0.40
Blue-collar 0.19 0.16 0.11 0.07 0.14 0.42 0.40 0.30 0.21 0.36
Others ‡ 0.19 0.16 0.11 0.04 0.14 0.42 0.41 0.29 0.12 0.35
Area of residence §
Urban 0.22 0.17 0.13 0.06 0.15 0.49 0.48 0.36 0.18 0.41
Semi-Urban 0.20 0.16 0.14 0.05 0.15 0.44 0.45 0.40 0.14 0.40
Rural 0.20 0.15 0.12 0.06 0.15 0.49 0.43 0.36 0.17 0.40
Sector
Public 0.20 0.18 0.13 0.04 0.16 0.39 0.40 0.31 0.08 0.35
Private 0.26 0.20 0.15 0.06 0.17 0.56 0.50 0.39 0.19 0.42
Both 0.15 0.10 0.08 0.04 0.10 0.44 0.44 0.36 0.23 0.40
Total 0.22 0.17 0.13 0.06 0.15 0.47 0.45 0.36 0.17 0.40
* All live births and all cycles during the mean 1.5 years treatment period. † One live birth per woman during the mean 1.5 years treatment period. 
‡ Entrepreneurs, students, pensioners, unemployed, and women with an unclassified or unknown position. § Excluding women with unknown area 
of recidence (n = 23).Page 4 of 8
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year treatment period succeeded (Table 2), while the
number of needed cycles per live birth among blue-collar
women was higher. Except for the oldest women, the total
expenditure and the proportion of public expenditure
were higher among blue-collar women than among
upper-white collar women (Table 4). Due to the higher
use of IVF, in every age group, the public expenditure was
about two-fold for upper white-collar women compared
to blue-collar women (Table 5).
Women treated in the private sector received more cycles
than women in the public sector, and the women treated
both in the public and in the private sector ('both sector
users') received the most cycles (Table 1). Success was
poorest among both sector users (Table 2) and their live
births were the most costly (Table 4).
No remarkable regional differences were found according
to the urbanity of the living area (Table 1, 2 and 4).
Discussion
Among infertile women in the care system, older women
with poorer success rates (i.e. increased need) received
more treatments, and expenditures per live birth were
much higher among them than among younger women.
The expenditures per population were lower among older
women, since fewer older women were treated. Because
no data relating to the desire for a child by age were avail-
able, it is not certain whether all younger and older
women wishing to have a baby were in the IVF care sys-
tem. Women from a higher socioeconomic position had
more often used IVF care, and total and societal costs per
population were higher than among women from the
lower socioeconomic position. Regional differences were
not remarkable.
Are these results reliable? Our data was based on adminis-
trative registers, and we think that the results on treatment
and success rates by socioeconomic characteristics are reli-
able. The group 'other' is a heterogeneous group that also
includes entrepreneurs. Since we did not have any infor-
mation on the size of their enterprise, we could not define
a socioeconomic position for them. Due to the small pro-
portion (2%), it is unlikely to bias our results based on
socioeconomic position. However, grouping into private
Table 5: Total expenditure on IVF treatment * per female 
population by women's background characteristics (in euros).
Total expenditure, euros
Age 20–29 30–34 35–39 40–49 Total
Socioeconomic position
Upper white-collar 100 200 170 50 110
Lower white-collar 80 160 110 20 80
Blue-collar 50 100 70 20 50
Others † 10 30 20 8 20
Area of residence ‡
Urban 40 120 100 20 60
Semi-Urban 50 110 70 20 50
Rural 60 110 70 20 50
Total 40 120 90 20 60
* Excluding IVF women aged 50 years or more (n = 16). † 
Entrepreneurs, students, pensioners, unemployed, and women with 
an unclassified or unknown position. ‡ Excluding women with 
unknown area of residence (n = 23).
Table 4: Number of cycles needed to live birth, total expenditure and the proportion of public expenditure (%) per live birth by 
women's background characteristics
Number of cycles per live birth Total expenditure, euros Public expenditure, %
Age 20–29 30–34 35–39 40+ Total 20–29 30–34 35–39 40+ Total 20–29 30–34 35–39 40+ Total
Socioeconomic position
Upper white-collar 4.1 5.6 7.5 15.8 6.6 12130 13200 17780 38440 16130 60 59 58 50 57
Lower white-collar 4.3 5.8 7.3 19.3 6.3 12260 13500 16930 43300 15300 63 62 61 52 61
Blue-collar 5.3 6.1 9.0 13.8 6.9 14300 14690 20500 31840 16910 65 63 62 53 62
Others * 5.2 6.3 8.9 23.8 7.1 14080 14600 20390 59310 17340 63 63 59 52 60
Area of residence †
Urban 4.5 5.6 7.8 17.0 6.5 12400 13280 18120 41100 15830 62 61 59 51 59
Semi-Urban 4.8 6.2 6.8 22.2 6.6 14310 14310 16350 48700 16250 65 63 59 53 61
Rural 4.7 6.4 7.8 15.6 6.7 13400 14800 18030 33200 16100 64 64 62 53 62
Sector
Public 5.0 5.6 7.6 27.3 6.1 13600 13370 17300 38770 14710 76 76 76 78 76
Private 3.9 5.3 6.9 15.8 6.2 10590 11840 16170 40520 14880 51 51 50 49 51
Both 6.9 10.1 12.8 23.0 10.5 20190 22580 26640 42830 23870 63 63 62 58 62
Total 4.7 6.0 7.8 17.4 6.7 12850 13660 17830 40660 15940 63 62 60 52 60
* Entrepreneurs, students, pensioners, unemployed, and women with an unclassified or unknown position. † Excluding women with unknown area 
of residence (n = 23).Page 5 of 8
(page number not for citation purposes)
BMC Health Services Research 2007, 7:210 http://www.biomedcentral.com/1472-6963/7/210and public sectors and expenditures have to be interpreted
with reservations due to the various estimations made.
The cost estimates of interventions and examinations in
private clinics were based on the prices in one clinic. But
that clinic was one of the biggest and when we asked
prices from several clinics, they recommended obtaining
data from this clinic and to use it as the reference. Our
basic data on expenditures of treatments and drugs were
based on the situation in the late 1990s. We do not, how-
ever, consider this a drawback because all expenditures
were inflated to correspond to 2005 prices, and we
focused primarily on describing the differences in expen-
ditures by women's age and socioeconomic position
rather than the exact amount of euros. Furthermore, our
cost estimation of a successful IVF cycle is in accordance
with an earlier Finnish study [14] as well as earlier cost cal-
culations by age that have included the same components
as used in our study [10]. However, only some of the
actual costs were taken into account, the costs excluded
being non-routine radiological and laboratory tests and
all indirect costs such as travel costs and sick leaves. Fur-
thermore, the costs of complications as well as pregnancy
and birth costs that are known to be higher among older
women were not included. Had all costs been included,
the total expenditures may have been higher for the older
women and possibly also for rural women due to the
longer distances travelling to care facilities. The impact on
socioeconomic differences remains unclear.
Traditionally the discussion on unfairness in health care
has focussed on socioeconomic position and gender and
less on age. As expected, there were fewer older than
younger women in the care system, because childbearing
is usually started earlier than 35 years. The mean age of
maternity is 30 years in Finland [16]. However, if older
women sought IVF treatment, they received more cycles
because of lower success, and the expenditure of a live-
birth increased according to age due to the increased
number of cycles and amount of expensive drugs in the
cycles. Pregnancy and birth complications and poor foetal
outcomes in general increase by age [17,18] suggesting
that expenditures of pregnancy and child birth of older
women would also increase by age. Thus, if IVF resources
are scarce, it would be wise to concentrate on treating
younger women. On the other hand, it can be argued that
age should not be a reason to turn women away from IVF,
because for older women, IVF may offer the last chance to
become pregnant and have a child [19]. Should older
women with greater need receive more resources than
younger women? From a public health perspective treat-
ing older women with increasing costs and risks and
decreasing success of IVF is not wise. Furthermore, if the
older women's desire for children increases i.e. care seek-
ing increases, which has already been reported in the
United Kingdom [20], the problem of resource allocation
will grow in the future. Both the scarce health care
resources and the increasing need for prioritisation speak
for focusing treatments on women in their normal child-
bearing age.
Live births were most costly among 'both sector users' in
our study. Their success per cycle was the poorest, but due
to many attempts they succeeded as well on average as all
women taken in total in this study; 40% of them received
a child. Some of them may have been women who went
to a private clinic while being on the waiting list (i.e. wait-
ing for access to care) for the public sector [21]. Some may
have been women who had poor prognosis and after
unsuccessful treatments in one clinic sought treatments in
other clinics. From 1996 to 1998 in Finland no waiting
lists existed in the private sector but in the public sector
couples had to wait between one and two years. In 2005
the situation had changed due to the new time-frames for
receiving care stipulated by the Ministry of Social Affairs
and Health [22]. The longest waiting period is stipulated
to be 6 months in the public sector. However, an age-limit
of 40 years is still in force in the public sector.
In Finland, over 60% of IVF treatments are provided in the
private sector and women from the highest socioeco-
nomic position are overrepresented in the private sector
[7]. In spite of the reimbursement of private services, the
private expenditure remains higher i.e. more of women's
own financial resources are needed for treatments in the
private sector compared to the public sector. The use of
private services is likely to create unfairness also in Fin-
land. However, the unfairness is smaller than in countries
where IVF is not covered by health insurance [23,24]. In
the United Kingdom where 80% of IVF is given in the pri-
vate sector, authorities have warned that IVF is becoming
more commercial and people with insufficient income are
in danger of remaining without treatments [25]. Accord-
ing to the review by Dawson et al.[26], the most common
reasons for inability to obtain IVF treatment have been
financial.
It can be asked what priority should be given to infertility
treatments compared to other treatments in health care.
As in other countries [4,27,28], prioritizing has been indi-
rectly discussed in Finland: Should infertility be consid-
ered a disease or not, should treatments be given only for
medical reasons (diagnosed infertility) or also for social
reasons, and who should have the right to treatments or
eligibility? Prioritization has not, however, been discussed
explicitly, even though IVF is clearly prioritized by
women's age.
For some infertile couples the adoption of a child is an
alternative to infertility treatment. However, adoption is
costly for couples, too. In Finland, only foreign adoptionsPage 6 of 8
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infertility treatments are covered from public funds, the
adoption costs should be covered, too. In the late 1990s
Finnish couples had to pay all the expenditures of adop-
tion themselves, but since 2003 parents adopting a child
from abroad can claim an adoption grant from the Social
Insurance Institution to offset some of the adoption cost.
The adoption grant is a tax-free, one-time payment. Its
amount depends on the child's country and varies
between EUR 1900 to EUR 4500. According to present
study, the society covers about 60% of IVF expenditures
i.e. EUR 9600 per IVF live birth, which is about 2- to 5-
fold compared to the coverage of adoption.
Besides financial factors other factors also related to soci-
oeconomic position may be important in seeking or using
infertility treatments. They include recognition of fertility
problems, attitudes towards health and medical treat-
ment, social support, health status, and prior contacts and
experiences with health care [6,29].
In our study expenditures per live birth were somewhat
higher among women from the lower socioeconomic
position, but due to far more frequent use of IVF services,
the expenditures per population were greater among
women from higher socioeconomic position. Does this
indicate unfairness in the care provision? If fewer blue-
collar women were not as willing to use or did not need
IVF services as much as white-collar women, this differen-
tiated allocation cannot be considered as inequality. But if
services are organized such that women do not have the
same possibility to use them, it is unfair [30]. In this study
it was not possible to examine the reasons for the use or
non-use of IVF. Neither was it possible to study whether
the treatments or the quality of care varied by different
socioeconomic positions. In France, despite equal use of
IVF, a deeper analysis showed that women from lower
positions faced greater risks and lower benefits [6]. How-
ever, based on the fact that the most of IVF is given in the
private sector and that highly educated people are used to
going to the private sector compared to people with lower
education we think that the latter is more likely in Fin-
land. Poorer success (live-births per treated woman and
higher number of cycles per live birth) among blue-collar
women in our study may be related to more serious infer-
tility; infertility-related risk factors like smoking and obes-
ity are more common among blue collar women [31].
Access to IVF services can vary between geographical areas
even in countries where IVF is publicly funded [32]. In
Finland we did not find remarkable regional differences in
the use of IVF [7] and likewise in the current study, there
were no differences found in the resource allocation.
It is difficult to determine an optimal and equal age to
stop the resource allocation for IVF. Treatment of selected
women aged 40–43 has been found to be quite successful
[10,19] and natural pregnancies also occur for women in
their forties. However, a given age-limit could be a signal
that encourages women to attempt to give birth during the
normal fertile age. Social and family policy should pro-
mote circumstances that are suitable for childbearing at a
young age. As Chavkin [33] and Stillman [34] have
pointed out that this is a big challenge especially for coun-
tries that lack policies supporting parents who both work.
Conclusion
This study shows that the resources used for IVF varied by
women's age and socioeconomic position. IVF-children of
older women involve more expense due to the lower suc-
cess rates of IVF. Women from higher socioeconomic
positions used more IVF resources than other women.
Women and men need information on declining fertility
by age as well as the complexity of IVF. Causes of unequal
use of IVF services should be studied further, and resource
allocation for high technology should be made transpar-
ent.
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